Biotech

All Articles

OS Treatments refiles $6M IPO to cash HER2 drug, preclinical ADCs

.OS Therapies will certainly detail on the NYSE American sell substitution this morning via a $6.4 t...

ALX's waning CD47 feedback fee sends sell spiraling down

.ALX Oncology's stage 2 stomach cancer response fee has actually compromised. After seeing its CD47 ...

Ionis centers eye health condition coming from targets of Roche-partnered possibility after data let down

.An Additional of Ionis Pharmaceuticals' essential midphase readouts has actually fallen short of ex...

Biogen's CEO claimed no dangerous sell 2023. He's ready to be daring

.While Biogen's pharma peers are hunting for late-stage resources along with little bit of danger, C...

Instil refills pipe in $2B biobucks cope with ImmunOnco

.Instil Bio has actually been actually a biotech looking for a pipeline after it scrapped its own le...

Biogen ignores Denali Alzheimer's collab

.Biogen has actually returned liberties to an early Alzheimer's ailment program to Denali Therapeuti...

Takeda faucets new head of US oncology organization-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of considerable management hirings, firings as w...

Vertex, beaten by AATD once more, loses 2 resources on discard stack

.Vertex's try to deal with a rare genetic disease has actually attacked one more problem. The biotec...

Vir gains 3 T-cell engagers from Sanofi, gives up 25% of team

.Vir Medical's second-quarter incomes record wasn't short of large headlines. The company invited a ...

Galapagos stops CAR-T cell therapy litigation over Parkinsonism case

.Galapagos has paused registration in a test of a BCMA-directed CAR-T cell treatment, pushing the br...